Fairvalue-Calculator Fairvalue-Calculator
EN DE

Dimed S.A (PNVL3) Fair Value & Analysis

Healthcare · BR · Market cap R$1.6B

PriceR$10.98
Fair ValueR$18.40
Upside+67.6%
Quality95/100
Evidence: High Range R$13.80 – R$22.99

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Dimed S.A (PNVL3) currently trades at R$10.98, while our model-based Fair Value estimate is R$18.40 — implying the stock looks roughly 67.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Dimed S.A. Distribuidora de Medicamentos sells medicines, perfumeries, personal hygiene and beauty products, cosmetics and dermocosmetics in Brazil. It sells its products through physical stores in retail industry. Dimed S.A. Distribuidora de Medicamentos was founded in 1920 and is headquartered in Eldorado do Sul, Brazil.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Dimed S.A (PNVL3) undervalued?
As of Jun 24, 2026, our model estimates a fair value of R$18.40 versus a price of R$10.98 — about +68% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PNVL3?
Our 21-model fair value for Dimed S.A is R$18.40 (as of Jun 24, 2026), built from audited fundamentals. The current price is R$10.98.
What is the quality score of PNVL3?
Dimed S.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.